Day One Biopharmaceuticals at JP Morgan Healthcare Conference

I would not say that it's a gated decision as much as it is.

An aligned plan that allows us to really inform the phase III with the phase two results.

I know that fire life, one only just started here in November .

Sort of adult wrap altered solid tumors, how is enrollment going in that study have you seen any impact from the new variant.

And how.

How do we think about central timelines there on the data side.

Yes.

We havent guided and wont at this point to when data will be available from that Fireeye, one monotherapy component RF Tam to comment on the status of enrollment in the study itself. Once we announce our first patient treated back.

The end of two.

<unk> 2021 study.

Study remains on track, it's open at least six sites as of today and the number of sites looking to initiate in the next month or two as you know the study is enrolling patients with.

Solid tumors are adolescents and adults with solid tumors that are relapsed and have <unk> fusions <unk> fusions of wrap one amplifications. These are relatively uncommon lesions BRAF wild type fusion represent about 1% of the genomic alterations found in relapsed adult solid tumors and so we are employing a number of strategies, including choosing clinical proof.

The sequence of number of patients and can readily identify these patients.

Also creative ways of either bringing patients from.

Geographies or places in the country are places around the world.

This trial opened two sites that have the trial open or bringing the trial sites, where it's not open it just in time manner. So we remain confident that we'll be able to.

True.

Dependent of any of the effects of the pandemic.

Overcoming.

The relative rarity relative scarcity of these patients were able to find them as a place that we've chosen.

And then on.

Sort of the.

The combination with Conservative I think the guidance here is to start that phase one b to study this quarter with day one on one.

What are the gating factors to starting that.

Sam you want to comment on so we are on track to protocol.

Protocol has been finalized for.

A couple of months now and we're in the process.

Of getting it through the site initiation process and we aim to be on track for initiating sites this quarter.

Yeah.

And maybe final question for me here I don't see any questions in the portal, but final question for me here, which is.

How should we think about additional business development to kind of supplement the pipeline here with day, one on one kind of searches.

Thanks for the question Mark on what Charles answer that one as well, yes sure.

We've looked at business development as part of the core.

As to what we do here at day, one we've invested in the very early from our standpoint.

We're active in looking at multiple opportunities on a regular basis also as you know.

Finding an excess of looking to the next thing that we find compelling doesn't necessarily hang on a calendar as neatly as we'd like so the timing of it does offer a shift but as we demonstrated with the in license of the Mac earlier last year, we are acutely attuned to the market. When we find something that we think fits in our strategy and what we want to proceed with we will aggressively.

Certainly pursue that opportunity.

Great.

Well I don't see any more questions in the queue and so Jeremy.

Jeremy and team I wanted to thank you guys. So much for super productive session here.

I Hope you guys have a great rest of the conference.

Thanks, Ana Com. Thanks, again for the opportunity I Hope you have a good conference as well take care.

Okay.

[music].